When we expanded the antibody treatment to overnight and used primary BMDMs, which exhibited a higher phagocytic activity than established RAW264.7 macrophages, we further confirmed a higher level of VEGFA uptake by the BMDMs in co-culture with cancer cells after treatment with the BsAb than after treatment with the combination of anti-VEGFA and anti-HER2 antibodies. The gene discussed is VEGFA; the disease is cancer.